Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0344232 (blurred vision)
 2,072 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tears-which contain fibronectin, growth facors, and vitamins that support the migration, proliferation, and differentiation of the conjunctival and corneal epithelium-nourish, protect, and refresh the eye. An inadequate tear film produces a variety of symptoms (ocular irritation, itching, burning, eye strain or fatigue, photophobia, a foreign-body sensation, a sharp stabbing pain, blurred vision) that wax and wane in intensity and are characteristic of disorders such as dry eye (keratoconjunctivitis sicca) and neurotrophic keratitis. In patients for whom commercially manufactured eye drops fail to provide relief from the symptoms of those conditions, autologous serum eye drops (plasma eye drops, serum eye drops) have proven very effective. In this report, we examine the present case studies that reveal the efects of autologous serum eye drops on the signs and symptoms of both dry eye and neurotrophic keratitis. A procedure for preparing autologous eye drops is included.
...
PMID:Autologous eye drops for the treatment of dry eye and neurotrophic keratitis. 2396 23

Posterior vitreous detachment (PVD) is a common phenomenon in the aging eye. However, this may be complicated by persistent symptomatic vitreomacular adhesions that exert tractional forces on the macula (vitreomacular traction; VMT). VMT itself may be associated with epiretinal membrane formation and the development of idiopathic macular holes (IMH). Such pathologies may cause visual disturbances, including metamorphopsia, photopsia, blurred vision, and decreased visual acuity, which impact an individual's quality of life. Technologies such as optical coherence tomography allow an increasingly more accurate visualisation of the macular anatomy, including quantification of macular hole characteristics, and this facilitates treatment decision-making. Pars plana vitrectomy remains the primary treatment option for many patients with VMT or IMH; for the latter, peeling of the inner limiting membrane (ILM) of the retina has shown improved outcomes when compared with no ILM peeling. The development of narrow-gauge transconjunctival vitrectomy systems has improved the rate of visual recovery following surgery. Ocriplasmin, by degrading laminin and fibronectin at the vitreoretinal interface, may allow induction of PVD in a non-invasive manner. Indeed, clinical studies have supported its use as an alternative to surgery in certain patient populations. However, further research is still needed with respect to greater understanding of the pathophysiology underlying the development of VMT and IMH.
...
PMID:Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. 2410 69